Rhopressa

Active Ingredient(s): Netarsudil Dimesylate
FDA Approved: * December 18, 2017
Pharm Company: * AERIE PHARMS INC
Category: Vision / Eye Health

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Rhopressa Overview

Netarsudil (trade name Rhopressa) is a drug for the treatment of glaucoma. In the United States, the Food and Drug Administration has approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.[1] References ^ "Aerie (AERI) Gets Early FDA Approval for Lead Drug Rhopressa". December 19, 2017. This pharmacology-related article is a stub. You can help Wikipedia by expanding it. v t e

Read more Rhopressa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Netarsudil

Recent Rhopressa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Rhopressa: (1 result)

Sorted by National Drug Code

• 70727-497 Rhopressa .285 mg/ml Ophthalmic; Topical Solution/ Drops by Aerie Pharmaceuticals Inc.

Other drugs which contain Netarsudil Dimesylate or a similar ingredient: (1 result)